Once considered niche treatments for diabetes, GLP-1 medications have rapidly gained traction as both a front-line diabetes management drug and mainstream obesity interventions, with usage surging 300% in just a few years! In 2022 the American Diabetes Association (ADA) moved GLP1’s to a front-line drug meaning diabetic patients were no longer required to try a different medication first. As more than one-third of U.S. adults meet clinical criteria for GLP-1 use, employers, payers and providers face urgent questions: How sustainable is the current trajectory? What are the true clinical and economic returns? And how should coverage evolve in 2025 and beyond?
Hear Tim Sullivan, pharmacist and benefits strategy leader at PerformRx, and John Crable, lead consultant and employee benefits expert, as they unpack the latest data and explore the future of GLP-1s in the U.S. healthcare system. Participants will:
- Understand the scale and drivers of GLP-1 adoption
- Evaluate the economic impact on employers and payers
- Assess coverage gaps and equity implications
- Forecast the future of GLP-1 strategy in employer plans